Journal article
18F-FDG PET or PET/CT in Mantle Cell Lymphoma.
- Albano D Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy. Electronic address: doalba87@libero.it.
- Treglia G Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Bellinzona and Lugano, Switzerland; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Gazzilli M Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
- Cerudelli E Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
- Giubbini R Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
- Bertagna F Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
- 2020-03-15
Published in:
- Clinical lymphoma, myeloma & leukemia. - 2020
English
The aim of this systematic review was to examine published data about the potential role of Fluorine-18-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (18F-FDG PET or PET/CT) in patients affected by mantle cell lymphoma (MCL). A comprehensive computer literature search of Scopus, PubMed/MEDLINE, and Embase databases was conducted, including articles indexed up to November, 2019; 25 studies or subsets in studies analyzing the value of 18F-FDG PET or PET/CT in patients with MCL were eligible for inclusion. From the analyses of the selected studies, the following main findings are described: (1) MCL are 18F-FDG-avid in most of cases, especially nodal lesions, but bone marrow and gastrointestinal disease localizations have low 18F-FDG avidity; (2) 18F-FDG PET/CT seems to be helpful in staging setting, showing a better diagnostic performance than conventional imaging and a positive impact on clinical stage; (3) 18F-FDG PET/CT is useful in evaluating treatment response, especially after chemotherapy and transplantation; and (4) metabolic response after therapy seems to have a prognostic role. Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, MCL is an 18F-FDG-avid lymphoma in most of the cases, with the exception of bone marrow and gastrointestinal disease. Moreover, 18F-FDG PET/CT seems to be useful in evaluating treatment response and prognosis.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.clml.2020.01.018
- PMID 32169480
- Persistent URL
- https://sonar.ch/global/documents/731
Statistics
Document views: 54
File downloads: